title: Photodynamic therapy for juxtafoveal choroidal neovascularization in myopic eyes.
abstract: OBJECTIVE
  To report the results of photodynamic therapy in myopic patients with juxtafoveal choroidal neovascularization (CNV).
  
  
  METHODS
  Interventional case series.
  
  
  METHODS
  Three consecutive myopic patients with juxtafoveal CNV were treated by photodynamic therapy with the same protocol as the one used to treat subfoveal CNV. Visual acuity was measured on Early Treatment Diabetic Retinopathy Study (ETDRS) charts by an independent observer. Fluorescein angiography was performed 6 and 12 weeks after photodynamic therapy and then every 12 weeks.
  
  
  RESULTS
  In all three patients, one treatment of photodynamic therapy using verteporfin resulted in the involution of the CNV and improvement in best-corrected visual acuity from 20/50 or 20/40 to 20/25 or more. No retreatment was required during follow-up, which lasted for 12 to 24 months (mean = 17 months).
  
  
  CONCLUSIONS
  Photodynamic therapy may be an effective treatment for juxtafoveal CNV in myopic eyes.
authors.affiliation: Centre Ophtalmologique d'Imagerie et de Laser, Paris, France. cilaser75@wanadoo.fr
authors.forename: Salomon Y
authors.initials: SY
authors.lastname: Cohen
authors.forename: Alexandra
authors.initials: A
authors.lastname: Bulik
authors.forename: Lise
authors.initials: L
authors.lastname: Dubois
authors.forename: Gabriel
authors.initials: G
authors.lastname: Quentel
mesh_terms: D000328:Adult; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D008875:Middle Aged; D009216:Myopia / Q000150:complications*; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins / Q000627:therapeutic use*; D016896:Treatment Outcome; D000077362:Verteporfin; D014792:Visual Acuity
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin